Life Therapeutics (ASX: LFE) announced today that it has increased its forecast for the FY 2006/07 as a result of a significant expansion and planned expansions in its United States operations.
Leading cell therapy company, CyGenics Limited (ASX: CYN), today announced its results for half year from 1 July to 31 December 2005.
Apollo Life Sciences (ASX: AOP) today announced the appointment of Mr Bill Moss AM as an independent non-executive director of the company.
Life Therapeutics (ASX: LFE) has been granted an FDA license to collect hyperimmune plasma used to combat infection caused by the influenza virus. The FDA approval process, originally scheduled to take 12 months, was completed in 97 days, over seven months ahead of schedule.
Leading cell therapy services company CyGenics Ltd. (ASX: CYN) today announced the appointment of Mr Alberto J. Bautista to its Board of Directors, as a non-executive director.
Leading cell therapy company CyGenics Ltd. (ASX: CYN) announced that it will be part of a new international collaborative effort to develop new treatments for cancer. This will be done via the novel approach of developing and mobilising immune cells outside the human body.
Leading cell therapy company CyGenics Ltd. (ASX: CYN) today announced the formation of CordLife Sciences (India) Private Limited, a cord blood banking company. The new company will open its head office in Kolkata.
